IOncology

Editor’s Note: The 2025 China Conference on Holistic Integrative Oncology (CCHIO), jointly organized by the Chinese Anti-Cancer Association (CACA) and the Tengchong Scientist Forum Organizing Committee Office, and co-hosted by…

Editor’s Note On November 8, 2025, during the China Conference on Holistic and Integrative Oncology (CCHIO), the China Anti-Cancer Association (CACA) and the American Association for Cancer Research (AACR) jointly…

Editor's note: At the recently concluded 13th Federation of Asian Clinical Oncology (FACO 2025) Annual Meeting, Oncology Frontier, together with International Hepatology, interviewed Dr. Su Jiayong from the Affiliated Cancer…

Editor’s Note: China, Japan, South Korea and other East Asian countries share a high prevalence of hepatobiliary and pancreatic tumors, yet current treatment options still fall short of clinical needs.…

China, Japan, and other Asian countries represent the regions with the highest global incidence of gastric cancer. In China, most patients are still diagnosed at advanced stages, losing the opportunity for curative surgery. Effective systemic therapies are therefore critical to improving survival. In recent years, innovative therapies—particularly antibody–drug conjugates (ADCs)—have shown promising results. Among them, the HER2-targeted ADC trastuzumab deruxtecan (T-DXd) has achieved success in key clinical studies such as DESTINY-Gastric04, and is poised to reshape treatment paradigms starting from later-line settings. Asian investigators have played an important role in these practice-changing studies.

The 2025 China Conference on Holistic Integrative Oncology (CCHIO), jointly hosted by the Chinese Anti-Cancer Association (CACA), the Organizing Committee of the Tengchong Scientists Forum, the World Association of Integrative Oncology (WAIO), and the China Academy of Integrative Medicine Development Strategy, was held in Kunming, Yunnan from November 6–9, 2025. On November 7, the CACA–UICC Special Session, co-organized by CACA and the Union for International Cancer Control (UICC), concluded successfully. The session brought together experts and scholars from China and abroad to discuss comprehensive cancer management, global challenges and opportunities, and collaborative strategies for advancing global cancer control. 

Editor’s Note: The 2025 China Conference on Holistic and Integrative Oncology (CCHIO) was held in Kunming from November 6–9, 2025. The meeting was hosted by the China Anti-Cancer Association (CACA)…

Editor’s Note: At the 2025 ESMO Annual Congress, the breast cancer field once again witnessed multiple breakthroughs—ranging from the DESTINY-Breast09 study, which redefined first-line therapy for advanced HER2-positive breast cancer,…

Editor’s Note: The 2025 Second Forum on Innovative Anticancer Drug Clinical Research and the 9th East China Breast Cancer Salon, hosted by the Beijing Sci-Tech Medical Development Foundation and organized…